Windtree Regains Compliance with Nasdaq
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…
Year: 2023
Windtree Regains Compliance with Nasdaq
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…
Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform
MIDAS (mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically), in-licensed and…
Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform
MIDAS (mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically), in-licensed and…
Back-to-back Studies Validate geneType Breast Cancer Risk Test
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
Back-to-back Studies Validate geneType Breast Cancer Risk Test
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders
A highly selective HDAC-6 inhibitor Rescues motor-neuronal deficiencies in a Charcot-Marie-Tooth model To start IND…
ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders
A highly selective HDAC-6 inhibitor Rescues motor-neuronal deficiencies in a Charcot-Marie-Tooth model To start IND…
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
BOSTON, March 13, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
BOSTON, March 13, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
Patients treated with BIV201 experienced reduced ascites fluid buildup (p CARSON CITY, Nev., March 13,…
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
Patients treated with BIV201 experienced reduced ascites fluid buildup (p CARSON CITY, Nev., March 13,…
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future…
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future…
First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (“First Wave…
First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (“First Wave…
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
Chen Franco-Yehuda Chief Financial Officer Efrat Livne-Hadass Vice President of Human Resources HAIFA, Israel, March…
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
Chen Franco-Yehuda Chief Financial Officer Efrat Livne-Hadass Vice President of Human Resources HAIFA, Israel, March…
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
-The TGFβ1 and TGFβ3 isoforms are predictive –Validation of TGFβ2 as therapeutic target AGOURA HILLS,…
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
-The TGFβ1 and TGFβ3 isoforms are predictive –Validation of TGFβ2 as therapeutic target AGOURA HILLS,…